A Programmable Processor with 4096 Processing Units for Media Applications

Over the past few years, technology drivers for processor designs have changed significantly. Media data delivery and processing -- such as telecommunications, networking, video processing, speech recognition and 3D graphics -- is increasing in importance and will soon dominate the processing cycles consumed in computer-based systems. This paper describes a processo, called Linedancer, that provides high media performance with low energy consumption by integrating associative SIMD parallel processing with embedded microprocessor technology. The major innovations in the Linedancer is the integration of thousands of processing units in a single chip that are capable to support software programmable high-performance mathematical functions as well as abstract data processing. In addition to 4096 processing units, Linedancer integrates on a single chip a RISC controller that is an implementation of the SPARC architecture, 128 Kbytes of Data Memory, and I/O interfaces. The SIMD processing in Linedancer implements the ASProCore architecture, which is a proprietary implementation of SIMD processing, operates at 266 MHz with program instructions issued by the RISC controller. The device also integrates a 64-bit synchronous main memory interface operating at 133 MHZ (double-data rate, DDR), and a 64-bit 66 MHz PCI interface

Topotecan and pegylated liposomal doxorubicin combination as palliative treatment in patients with pretreated advanced malignant pleural mesothelioma

Background: Malignant pleural mesothelioma (MPM) is an aggressive disease with poor or modest responses to chemotherapy and dismal prognosis. In most of the cases the scope of the treatment is only palliative. In the current study, the combination of i.v. topotecan and pegylated liposomal doxorubicin (PLD) in advanced multi-treated MPM was tested. Primary objective was palliation of the symptoms, with the secondary ones being the establishment of the regimen's safety and efficacy. Patients and methods: Nine patients were enrolled (7 males/2 females, median age 57.5 years, ECOG performance status ≤ 2), having progressed after 2 or 3 lines of chemotherapy including pemetrexed and cisplatin. Main symptoms were dyspnea, cough, chest pain, fatigue, and anorexia. The treatment included topotecan 1.2 mg/m2 i.v. on Days 1-3 and PLD 40 mg/m2 on Day 4, every 28 days. The patients received 4-8 chemotherapy cycles (median 5.8). Results: In all cases, symptoms were significantly improved after the 2nd treatment cycle. Respiratory function tests showed considerable enhancement, while cough and pain were drastically reduced. All patients had objective clinical benefit, 1 patient achieving partial response and 8 stable disease. Median time to progression and overall survival was 7 and 9 months, respectively. The chosen dose of the topotecan/ PLD combination was well-tolerated with no Grade 3/4 toxicities. Quality of life, as it was evaluated by the QLQ-C30 and QLQ-LC13 questionnaires, had improved scores especially the ones referring symptomatology. Conclusion: The current study shows a significant palliative effect of the topotecan/ PLD combination in pretreated patients with advanced MPM. ©2012 Dustri-Verlag Dr. K. Feistle

Molecular characterization of a new intergenotype Norovirus GII recombinant

Human noroviruses (NoVs) of the Caliciviridae family are a major cause of epidemic gastroenteritis. The NoV genus is genetically diverse and recombination of viral RNA is known to depend upon various immunological and intracellular constraints that may allow the emergence of viable recombinants. In the present study, we report the development of a broadly reactive RT-PCR assay, which allowed the characterization of strain A6 at molecular level, established its genetic relationship at the sub-genogroup level and classified A6 strain at the sub-genotype level. The detection was carried out initially by enzyme-linked immunosorbent assay (ELISA) and the subsequent detection and molecular characterization of NoV strain was achieved by reverse transcription-PCR and sequencing. Based on the sequence analysis, A6 strain was revealed to belong to the GII genogroup of NoVs. Partial ORF1 gene sequencing analysis and complete ORF2 gene sequencing revealed that ORF1 and ORF2 belonged to two distinct genotypes GII/9 and GII/6, respectively, making obvious that A6 strain is a rare intergenotypic recombinant within the genogroup GII between GII.9 and GII.6 genotypes. A6 strain represents the first human NoV from Greece, whose genome has been partially (ORF1&ORF3) and completed (ORF2) sequenced. To our knowledge the recombination event GII.9/GII.6 in RdRp and capsid gene, respectively, that was revealed in the present study is reported for the first time

Complete nucleotide sequence analysis of the VP1 genomic region of Echoviruses 6 isolated from sewage in Greece revealed 98% similarity with Echoviruses 6 that were characterized from an aseptic meningitis outbreak 1 year later

The molecular characterization of two enterovirus strains (LR51A5 and LR61G3) isolated from the sewage treatment plant unit in Larissa, Greece, in May and June 2006 and the investigation of their relationship with enteroviruses of the same serotype isolated in Greece in 2001 and 2007 were performed by complete VP1 sequence analysis of the isolates. The close phylogenetic relationship and the high nucleotide similarity (98%) led to the conclusion that the virus isolated from sewage in 2006 was associated with that isolated from an aseptic meningitis outbreak 1 year later. Bootscan analysis of the VP1 genomic region revealed that intraserotypic multi-recombination events might have been involved in the evolutionary past history of the LR51A5 and LR61G3 isolates